NCT05856513View on ClinicalTrials.gov

Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 15, 2023

Primary Completion Date

July 4, 2023

Study Completion Date

July 4, 2023

Conditions
Hepatic ImpairmentPharmacokinetics
Interventions
DRUG

ZSP1273

Participants receive ZSP1273 orally.

DRUG

ZSP1273

Participants receive ZSP1273 orally.

DRUG

ZSP1273

Participants receive ZSP1273 orally.

Trial Locations (1)

Unknown

The First Hospital of Jilin University, Jilin

All Listed Sponsors
lead

Guangdong Raynovent Biotech Co., Ltd

INDUSTRY